Details Of Merck Research Labs Leadership Shuffle Emerge
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck recently has embarked on what appears to be a major restructuring of its R&D leadership under R&D head Roger Perlmutter, but the company has yet to make an official announcement regarding appointments and dismissals.
You may also be interested in...
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Ketamine May Shake Up The Treatment Of Major Depression
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
The Disruptive Impact Of Retail Clinics
Retail health clinics are undergoing an intense period of partnering and business model change. Although the value proposition is rock solid, the real test will be whether clinics can offer complementary services to traditional primary care, and working with provider groups, help achieve the goal of population health management.